Open-Label Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral Ibrexafungerp (SCY-078) as an Emergency Use Treatment for Patients With Candidiasis, Including Candidemia, Caused by Candida Auris
Latest Information Update: 13 Nov 2024
Price :
$35 *
At a glance
- Drugs Ibrexafungerp (Primary)
- Indications Candidaemia; Invasive candidiasis
- Focus Registrational; Therapeutic Use
- Acronyms CARES
- Sponsors SCYNEXIS
- 06 Nov 2024 According to a SCYNEXIS media release, clinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to GSK, triggering a $10 million development milestone payment to SCYNEXIS, received in Q3 2024
- 28 Mar 2024 According to a SCYNEXIS media release, final study reports from FURI, CARES, SCYNERGIA, NATURE, and VANQUISH studies are anticipated to be delivered to GSK in the mid of 2024, which would trigger a $10 million development milestone payment to SCYNEXIS.
- 28 Mar 2024 According to a SCYNEXIS media release, top line data from the CARES study has been received and is positive and consistent with previously disclosed results from interim analyses.